Bezlotoxumab denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for bezlotoxumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Bezlotoxumab for Medical Necessity

A medical-necessity denial means Aetna's clinical reviewer determined the submitted documentation did not establish that bezlotoxumab was required rather than merely convenient or preferable. For bezlotoxumab — a monoclonal antibody used to reduce the risk of recurrent Clostridioides difficile infection — Aetna's coverage policy typically ties medical necessity to specific risk factors that elevate the probability of recurrence. When the record lacks explicit documentation of those risk factors, reviewers default to denial.

## Why This Denial Is Appealable

Medical necessity denials are among the most frequently overturned on appeal because they hinge on documentation completeness rather than clinical merit. If your prescriber considered and documented the relevant recurrence-risk profile, that information may simply not have been transmitted to Aetna in a format the reviewer could evaluate. A well-structured appeal that maps every medical-necessity criterion in Aetna's policy to a corresponding chart fact closes that gap.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 and ACA-compliant plans, you have the right to a full-and-fair review. Submit the internal appeal within the deadline stated on the denial letter (commonly 180 days).
• External review (ACA §2719): If the internal appeal is denied, an Independent Review Organization conducts a binding review. File within approximately four months of the final internal denial.
• Expedited track: If delay poses serious health risk, request expedited review in writing with prescriber support.

## Concrete Appeal Steps

1. Request Aetna's current published medical or coverage policy for bezlotoxumab to identify every medical-necessity criterion. 2. Obtain the FDA-approved prescribing label (Zinplava) and note the indication, including the patient-population language. 3. Have your prescriber perform a documented chart review specifically addressing each policy criterion. 4. Submit a written appeal with a prescriber letter and supporting records addressing each criterion individually.

## Documentation to Gather

• Diagnosis documentation: Laboratory confirmation of C. difficile infection with dates.
• Recurrence history: All prior C. difficile episodes, dates, antibiotic courses used, and outcomes documented in the chart.
• Clinical risk factors: Any factors identified in the chart and the FDA label as relevant to recurrence risk — documented with objective clinical evidence, not just assertion.
• Ongoing antibiotic treatment: Name and course of the antibiotic being used concurrently, to establish the treatment context the FDA label requires.
• Prescriber medical-necessity letter: Explicitly addressing each criterion in Aetna's policy with corresponding chart citations (note number, date, and finding).

## Criteria-Mapping Structure

Create a table with three columns: (1) Aetna policy criterion — copied verbatim from the published policy; (2) FDA label language — the corresponding indication or patient-population text; (3) chart evidence — the specific note, lab, or clinical finding that satisfies the criterion. Your prescriber should review and sign this table or reference it in their letter. This format forces the reviewer to engage with each requirement individually and makes it very difficult to sustain the denial on completeness grounds.